Yükleniyor... / Loading...
This study examined the role of genetic information and shared decision making (through counseling, questionnaires and chart review) in improving care for patients with advanced non-small cell lung cancer (NSCLC). Newly diagnosed stage IV patients who had exhausted targeted therapy options were eligible. The study had no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Newly diagnosed with advanced NSCLC (stage IV a-c) that are wild-type for activating genetic alterations (EGFR, ROS 1, and ALK). * May or may not be candidates for immune checkpoint therapy. * May have had 1-any number of prior systemic therapy regimens. * If prior systemic regimen, must have progression disease at time of evaluation. * Untreated brain metastases permitted. * Completed pathological analysis of tumor tissue. * Patients who have exhausted targeting therapy options. * Can speak and read English. * All participants must be willing to comply with all study procedures and be available for the duration of the study. * Providers: Those who treat NSCLC patients as described above. Exclusion Criteria: • There are no specific exclusions in this trial for particular medical conditions, comorbidities, or performance status. Any patient deemed appropriate to be considered for evaluation and/or treatment would be appropriate to include in this trial.